Goldman Sachs Maintains Geron(GERN.US) With Buy Rating
Goldman Sachs analyst Corinne Johnson maintains $Geron(GERN.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 53.6% and a total average return of 6.2% over the
Goldman Sachs Reaffirms Their Buy Rating on Geron (GERN)
Geron Corporation (NASDAQ:GERN): Hedge Funds Are Bullish On This US Stock to Buy Under $5 Now
Express News | Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer
Biologics by McKesson's RYTELOTM, FDA Gets Approval For Treatment Of Patients With Low- To Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia
Leerink Partners Initiates Geron(GERN.US) With Buy Rating, Announces Target Price $7
Leerink Partners analyst Faisal Khurshid initiates coverage on $Geron(GERN.US)$ with a buy rating, and sets the target price at $7.According to TipRanks data, the analyst has a success rate of 90.0%
Express News | Geron Corp : Leerink Partners Initiates Coverage With Outperform Rating; Target Price $7
Swelling Losses Haven't Held Back Gains for Geron (NASDAQ:GERN) Shareholders Since They're up 204% Over 3 Years
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation's (NASDAQ:GERN) Shift From Loss To Profit
Investing in Geron (NASDAQ:GERN) Three Years Ago Would Have Delivered You a 285% Gain
Geron Second Quarter 2024 Earnings: Beats Expectations
Express News | Geron Corp : B. Riley Raises Target Price to $5.5 From $5
Earnings Call: Geron Reports Promising Start for RYTELO in MDS Treatment
10-Q: Q2 2024 Earnings Report
Buy Rating Affirmed for Geron's Rytelo on Strong Launch and Positive Clinical Outlook
Geron (GERN) Reports Q2 Loss, Tops Revenue Estimates
Earnings Flash (GERN) GERON CORPORATION Reports Q2 Revenue $882,000, Vs. Street Est of $290,000
Geron GAAP EPS of -$0.10 In-line, Revenue of $0.88M Beats by $0.59M
Express News | Geron Corporation Reports Second Quarter 2024 Financial Results and Business Highlights